INTRODUCTION
Epithelial ovarian cancer is the seventh most common cancer in women worldwide, and the 5-year survival rate ranges from 30% to 50%. 1 Standard treatment consists of primary cytoreductive surgery (PCS) followed by platinumbased chemotherapy. 2,3 Currently, discussion on primary treatment of patients with advancedstage ovarian cancer who should undergo PCS or interval cytoreductive surgery is ongoing. 4 Two randomized trials showed the noninferiority of interval cytoreductive surgery in patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC to IV. 5,6 However, a post hoc analysis of this study showed that prognosis was favorable in patients with metastases , 45 mm and stage IIIC disease who undergo PCS. In contrast, patients with larger metastases and stage IV disease benefited more from interval cytoreductive surgery. 7 Recently, another single-institution analysis showed that the best survival outcomes were observed in patients deemed eligible for PCS. 8 Survival is strongly correlated with the size of residual tumor; therefore, the aim of cytoreductive surgery is to leave no residual tumor or at least a maximum diameter of , 1 cm. [9] [10] [11] The dilemma is that PCS that results in no residual disease may require extensive surgery with a subsequent higher risk of morbidity. 5 If at PCS extensive disease is present, surgery could be ceased, and neoadjuvant chemotherapy (NACT) with interval surgery could be a good alternative treatment. 4 Therefore, the identification of patients with extensive disease who are likely to have . 1 cm of residual tumor after PCS, defined as a futile laparotomy, is important. 12 Current, noninvasive diagnostic methods such as physical examination, ultrasonography, abdominal computed tomography (CT), and serum tumor markers like CA125 and carcinoembryonic antigen fail to predict completeness of surgery accurately. Although numerous investigators have tried to create prediction models that are based on various imaging techniques and clinical features, none of these models have proven to be useful to prevent futile laparotomy in daily practice. 13 On the basis of previous studies, we hypothesized that laparoscopy can reduce the number of futile laparotomies by predicting the outcome of PCS without increasing the risk of omitting primary surgery to patients with resectable disease or increasing the risk for complications. [14] [15] [16] To investigate this hypothesis, we conducted a multicenter, randomized controlled trial that used laparoscopy as a diagnostic tool to guide choice of primary treatment in patients with suspected advanced-stage epithelial ovarian cancer.
PATIENTS AND METHODS

Study Design and Participants
This randomized controlled trial was performed within eight gynecologic cancer centers in the Netherlands. Patients between 18 and 80 years of age with suspected advanced-stage ovarian cancer (FIGO stage IIB or higher 17 ) were eligible whenever PCS seemed possible after conventional work-up. Conventional work-up consisted of medical history, complete physical and gynecologic examination, measurement of serum tumor markers (CA125 and carcinoembryonic antigen), calculation of the Risk of Malignancy Index score, 18 sonography of the pelvic area, CTscan of the abdomen, and imaging of the thorax (CT thorax preferred). Biopsy was not obligatory in the conventional work-up because high suspicion of advanced-stage ovarian cancer was already the reason for surgical intervention. However, the presence of advanced-stage ovarian cancer was always histologically confirmed before the start of NACT.
Exclusion criteria were a World Health Organization performance status $ 3 or any contraindications for laparoscopy. Other exclusion criteria were presence of a large immobile pelvic tumor; imaging evidence of the presence of intrahepatic metastatic disease of . 1 cm; extraabdominal metastatic disease (not to exclude patients with only inguinal lymph nodes or pleural fluid); periaortic lymphadenopathy . 1 cm above the level of the renal veins; extensive peritoneal carcinomatosis at the diaphragmatic level; and extensive bowel mesentery involvement, which suggests that cytoreductive surgery that would result in , 1 cm of residual disease seemed not feasible or would increase the risk of major complications. In the presence of these signs of extensive disease, the patient was considered not eligible for PCS and thus not randomly assigned in the current study. 6 The decision about eligibility for PCS was made at a multidisciplinary session attended by a gynecologic oncologist, medical oncologist, pathologist, and radiologist.
Ethical approval was obtained from the medical ethics committee of the Academic Medical Center of Amsterdam (MEC10/183). All patients were treated in a gynecologic oncology center, and laparoscopies and cytoreductive surgeries were performed by an accredited gynecologic oncologist. Standard chemotherapy comprised six cycles of carboplatin and paclitaxel 175 mg/m 2 every 3 weeks.
Random Assignment and Masking
After written informed consent, participants were randomly assigned (1:1) to either diagnostic laparoscopy (intervention arm) or to PCS followed by chemotherapy (standard arm). Random assignment was performed centrally with a Web-based tool that used a permuted-block design and stratification by gynecologic cancer center. Participants and investigators were not masked to treatment allocation.
Procedure
In the intervention arm, diagnostic laparoscopy was performed within 3 weeks after random assignment. An open laparoscopy was performed to inspect the whole abdomen systematically. The decision that cytoreduction to , 1 cm of residual disease was not feasible was made by the gynecologic oncologist on the basis of the following laparoscopic findings: extensive agglutinated intra-abdominal metastatic disease (including spleen or retrohepatic area involvement), extensive serosa invasion of the intestines and/or mesenterial deposits (which would make multiple bowel resections of . 1.5 m of bowel necessary to reach complete cytoreductive surgery), and extensive (irresectable) peritoneal metastases at the diaphragmatic level. If PCS that would leave at least , 1 cm was considered feasible, PCS was performed and followed by six cycles of chemotherapy. If PCS with maximal effort to remove all tumor to , 1 cm of disease was considered not feasible at laparoscopy, patients were primarily treated with three courses of NACT followed by interval cytoreductive surgery. In the standard arm, all patients were assigned to PCS. The goal of surgery in all cases was to resect all macroscopic tumors. In both study arms, a second laparotomy was considered after three cycles of chemotherapy in case . 1 cm of residual tumor was left after the first surgical attempt. The amount and localization of residual disease was reported on a standard form by the gynecologic oncologist. Follow-up consisted of visits every 3 months for the first 2 years followed by visits every 6 months up to 5 years. Recurrent disease was reported if patients presented with clinical symptoms and laboratory results or image evidence showed recurrent disease.
Outcomes
The primary outcome measure of the study was a futile laparotomy, defined as residual tumor with a maximum diameter of . 1 cm after PCS. The aim of this study was to guide treatment decisions for either PCS or interval cytoreductive surgery, to reduce the number of patients subjected to multiple laparotomies, and to select patients suitable for PCS. Secondary outcomes were adverse events and progression-free and overall survival. Adverse events were graded by the Common Terminology Criteria for Adverse Events (version 4.0) and assessed during treatment and at each clinical visit.
Statistical Analysis
Analyses were performed on an intention-to-treat basis. We calculated the proportion of patients with futile laparotomies in each arm. We tested for differences with the x 2 test, or if a group contained fewer than five patients, the Fisher's exact test, with a two-sided significance level of .05.
In the survival analyses, survival time was considered censored at the time patients were last known to be alive or at the end of follow-up. Survival was compared by estimating Kaplan-Meier curves in each arm and tested by using the log-rank test. Hazard ratios were calculated with a Cox proportional hazards model. Progression-free survival was defined as time from random assignment until the date of clinical progression, recurrence, or death, whichever came first.
The rate of incomplete PCS (ie, leaving . 1 cm of residual disease) after conventional work-up in the Netherlands was estimated to be 40%. 10, 19 We hypothesized that laparoscopy would reduce this rate to 20%. To achieve a power of 80%, 90 participants per arm had to be included. With a consideration of 10% possible attrition, the trial sample size was set at 200 patients.
Statistical analysis was performed with SPSS version 23.0 software (IBM Corporation, Chicago, IL). This study was registered in the Netherlands Trial Register (NTR2644), and the study protocol has been published. 20
RESULTS
Patients
Between May 2011 and February 2015, we enrolled 202 patients. One patient was randomly assigned incorrectly because there was no suspicion of advanced-stage ovarian cancer; this patient was therefore excluded from all analyses. Data on the remaining 201 patients were included in the intention-to-treat analysis; 102 were assigned to receive laparoscopy before surgery and 99 to PCS (Fig 1) . All patients received a preoperative CT scan of the abdomen and lower thorax and a chest x-ray or CT scan of the thorax. The baseline characteristics were well balanced between the two treatment groups (Table 1) .
Definitive histologic diagnosis, FIGO stage, and histologic grade by Silverberg 21 were obtained after surgery ( Table 2 ). The final pathology showed adenocarcinoma of the ovary, tubes, or peritoneum in 174 (87%) of the 201 patients, with serous adenocarcinoma in the majority of cases. Ten patients (5%) had other malignancies. Fourteen patients (7%) had benign disease, equally divided between the groups. Among the 174 patients with ovarian cancer, 80% had FIGO stage IIIC or IV disease, equally divided between the groups.
In the laparoscopy group, 63 (62%) of 102 patients underwent PCS after laparoscopy; 39 (38%) of 102 patients were assigned to NACT followed by interval surgery. Reasons at laparoscopy to withhold from PCS were mostly because of extensive agglutinated intra-abdominal metastatic disease and extensive peritoneal metastases at the diaphragmatic level. In four of these patients, no ascopubs.org/journal/jco cytoreductive surgery was attempted because of progression while receiving chemotherapy or inoperability because of poor general condition. In the primary surgery group, 93 (94%) of 99 patients underwent PCS. One patient erroneously received a diagnostic laparoscopy despite allocation to primary surgery; she was assigned to NACT. Five patients in the primary surgery group experienced a deterioration of their physical condition after random assignment and were considered unfit for PCS; they were assigned to NACT. Four of these patients received interval surgery (Fig 2) .
Primary Outcome
Futile laparotomy that left . 1 cm of residual disease after primary surgery occurred in 10 (10%) of 102 patients in the laparoscopy group versus 39 (39%) of 99 patients in the primary surgery group (relative risk [RR], 0.25; 95% CI, 0.13 to 0.47; P , .001). In the laparoscopy group, 27 (27%) of 102 patients had any residual tumor (. 0 cm) versus 56 (57%) of 99 patients in the primary surgery group (RR, 0.47; 95% CI, 0.32 to 0.68; P , .001; Table 3 ). The per-protocol analysis for the entire study group showed similar results (Appendix Table A1 , online only). In the subgroup analysis of patients with confirmed stage IIIC or IVovarian cancer, only six (8%) of 71 patients in the laparoscopy group versus 32 (46%) of 69 patients in the primary surgery group underwent a futile laparotomy (Table 3) .
Secondary Outcomes
In the laparoscopy group, four (4%) of 102 patients underwent both primary and interval laparotomy versus 28 (28%) of 99 patients in the primary surgery group (P , .001; Table 3 ). 1.60 (1.0-3.5) Mean albumin before treatment (SD), g/dL 38.0 (6.9) 40.7 (5.9)
Abbreviations: BMI, body mass index; CEA, carcinoembryonic antigen; IQR, interquartile range; SD, standard deviation. resection in patients in whom complete cytoreductive surgery was feasible. No difference in extensive surgery between study groups was seen (Appendix Tables A2 and A3, online only).
In addition, analyses of the differences in the amount of residual disease per surgical strategy (primary or interval) were performed. No residual tumor was observed in 36 (57%) of 63 patients who underwent PCS in the laparoscopy group versus 37 (40%) of 93 patients in the primary surgery group (P 5 .006; Appendix Table A4 , online only) and in 14 (41%) of 34 patients and 16 (25%) of 63 patients in the subgroup with stage IIIC or IV ovarian cancer, respectively (Appendix Table A5 , online only). Complete remission after surgery and chemotherapy was seen in 65 (66%) of 99 patients in the laparoscopy group versus 65 (68%) of 95 in the primary surgery group (Appendix Table A2 ).
In the laparoscopy group, 22 patients had a grade 3 or 4 adverse event versus 26 in the primary surgery group (RR, 0.82; 95% CI, 0.50 to 1.35; P 5 .44). Only one complication was related to laparoscopy: a wound infection that required antibiotics. Port-site metastases after laparoscopy were reported in three patients; these patients had stage IIIC or IV ovarian cancer (Appendix Table A6 , online only). [22] [23] [24] Median duration of follow-up was 34.6 months in the laparoscopy group and 33.8 months in the primary surgery group. At the last time of follow-up (April 8, 2016), 46 patients had died in the laparoscopy group and 42 in the primary surgery group (RR, 1.11; 95% CI, 0.99 to 1.25; P 5 .07), which indicates comparable survival in both groups. Median progression-free survival was 13.7 months (interquartile range [IQR], 7.1 to 41.8 months) in the laparoscopy group and 15.2 months (IQR, 7.2 to . 34 months) in the primary surgery group (P 5 .88) with a hazard ratio of 0.97 (95% CI, 0.69 to 1.38). The median overall survival was 44.4 months (IQR, 16.8 to . 55 months) in the laparoscopy group and 46.3 months (IQR, 13.9 to 52.6 months) in the primary surgery group (P 5.94) with a hazard ratio of 1.33 (95% CI, 0.89 to 1.98; Appendix Table A7 , online only; Figs 3A and 3B ). Finally, a post hoc explorative survival analysis showed similar results if only patients with stage IIIC or IV ovarian cancer (n 5 140) were included (Appendix Table A8 , online only; Figs 3C and 3D). No difference in chemotherapy regimen between study groups was seen (Appendix Table A9 , online only).
DISCUSSION
In this multicenter, randomized controlled trial, we investigated the value of laparoscopy in the diagnostic work-up of patients with suspected advanced ovarian cancer. Laparoscopy to guide treatment decision making significantly reduced the percentage of futile PCSs (ie, leaving . 1 cm of residual disease). Furthermore, by using laparoscopy as a diagnostic aid, the number of patients subjected to multiple laparotomies was significantly reduced without increasing the complication rate.
Cytoreductive surgery with no residual disease (0 cm) was reached in 41% of the patients with stage IIIC or IV ovarian cancer who underwent PCS in the laparoscopy group and in only 25% of the patients in the primary surgery group (Appendix Table A5 ). These results are comparable to those reported in other multicenter studies that ranged from 17% to 46%. 5, 6, 8, [25] [26] [27] The strength of this study is the multicenter approach. All eight specialized oncologic centers in the Netherlands participated in this trial, which created an accurate reflection of current practice. The multicenter aspect of the study may be considered an advantage because of its generalizability. On the other hand, different treatment centers and gynecologic oncologists may have differing estimations of the selection of patients considered operable and the chance of futile laparotomies, which could have biased the results. We minimized this effect by establishing clear rules for patient selection and estimations at laparoscopic evaluation.
Because we based our inclusion criteria on conventional work-up and not on histologic biopsy, 13% of the included patients had either benign or borderline disease or a different origin of malignancy. Furthermore, patients with suspected stage IIB or IIIB ovarian cancer were also included because higher stage or more extensive disease cannot be excluded beforehand, and in these cases, PCS should always be considered. In contrast, the CHORUS (Primary Chemotherapy Versus Primary Surgery for Newly Diagnosed Advanced Ovarian Cancer) trial used stricter inclusion criteria (ie, included only patients with suspected stage III or IV ovarian cancer) and had 3% with benign, borderline, or different tumors in their population. 5 Patients might have been wrongly excluded in the current study in that they may have been considered as having unresectable disease after conventional work-up, which might have influenced the data. Several studies have tried to develop a noninvasive prediction model to predict operability, but none are 100% accurate. 13 However, during the inclusion period of the current study, more accurate prediction models for preoperative assessment became available. [28] [29] [30] At the start of our study, however, the Risk of Malignancy Index and CT assessment were part of the standard work-up in the Netherlands.
The reason for exclusion of patients with expected inoperable disease was to prevent patients from being subjected to laparoscopy or laparotomy when primary surgery was considered unfavorable beforehand. Recently, ASCO published a practice guideline that was based on a systematic review that propagated the same approach wherein all women with a high perioperative risk profile and low likelihood of cytoreduction to , 1 cm are recommended to receive NACT. 31 PCS is preferred if there is a high likelihood of , 1 cm of residual disease with acceptable morbidity. Furthermore, four other randomized clinical trials that compared primary surgery and NACT with interval surgery in patients with advanced-stage ovarian cancer concluded that NACT was noninferior and the extent of surgery diminished in the NACT arm with decreased complication rates. 5,6,24,32 From these results, we conclude that patients with extensive disease, such as large immobile pelvic tumor or extensive disease of the diaphragm, would benefit most from treatment with NACT. 31 In addition, Vergote et al 6 found no survival benefit for either treatment strategy. Therefore, survival was not taken as the primary end point in the current study.
Nevertheless, to our knowledge this randomized clinical study is the first to investigate the role of laparoscopy to prevent futile laparotomies in women with suspected advanced ovarian cancer. Several retrospective or prospective case series have described a diagnostic laparoscopy as a reliable tool to identify women suitable for PCS, but negative predictive values ranged from 69% to 96%, and heterogeneity of the studies made it impossible to draw firm conclusions. 16,33-36 A laparoscopy-based score developed in 2005 to 2006 by Fagotti et al 14,37 showed a positive predictive value of 100% and a negative predictive value of 70% for cytoreductive surgery with , 1 cm of residual disease. This score could not accurately discriminate among women who would be left with . 1 cm of residual disease after validation. 15, [38] [39] [40] [41] Recently, this model was updated by Petrillo et al 33 to show a higher discriminating performance of laparoscopy, with an area under the curve of 0.89 and a risk of futile laparotomy of 33%, that leaves any residual disease. Despite these limitations, all the aforementioned studies suggested an additive value of laparoscopy, which was the motivation for the current randomized trial.
In conclusion, if complete PCS seems feasible, diagnostic laparoscopy is an effective and safe tool to select patients in whom PCS will be successful in leaving (at least) , 1 cm of residual disease. Therefore, diagnostic laparoscopy should be considered in the diagnostic work-up of women with ovarian cancer to guide treatment selection for either PCS or NACT.
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